The EBV-transformed B lymphoblastoid cell line (B-LCL) JY was cultured in complete culture medium consisting of IMDM (BioWhittaker) supplemented with 8% FCS (Greiner), 100 IU/ml penicillin, and 2 mM l-glutamine. The processing-defective T2 cell line was a gift from Dr. P. Cresswell (Yale University, New Haven, CT). Melanoma cell lines (Mel603, M453, and FM3), renal cell carcinoma cell lines (MZ1851, MZ1774, and MZ1257), and mammary carcinoma cell line MCF7 were provided by Dr. P. Schrier (Leiden University Medical Center). Mammary carcinoma cell line ZR-75-1 was obtained from the American Type Culture Collection. Lung carcinoma cell lines GLC02 and GLC36 were provided by Dr. L. de Leij (University of Groningen, Groningen, The Netherlands). The CD40 ligand–transfected mouse L cell line 53 that was used for generation of activated B cells was donated by Dr. C. van Kooten (Leiden University Medical Center). PRAME cDNA was provided by Dr. P. Coulie (Ludwig Institute for Cancer Research, Brussels, Belgium). The PRAME-encoding insert was cloned into vector pDR2 (Invitrogen), conferring hygromycine resistance. The renal cell carcinoma cell line MZ1851 was transfected with pDR2-PRAME using Fugene (Boehringer) as transfection reagent. After 48 h, hygromycine (100 μg/ml) was added to select transfected cells. Hygromycine-resistant cells were tested by reverse transcription (RT)-PCR for PRAME expression.

Peptides were synthesized by solid phase strategies on an automated multiple peptide synthesizer (Abimed AMS 422) using 9-fluorenylmethyloxycarbonyl (Fmoc) chemistry. Short peptides for CTL inductions were dissolved in 20 μl DMSO, diluted in 0.9% NaCl to a peptide concentration of 1 mg/ml, and stored at −20°C before usage. The fluorescein (FL)-labeled reference peptide as used in the competition-based HLA-A*0201 binding assay was synthesized, labeled, and characterized as described earlier 54. The sequence of the FL-labeled peptide was FLPSDYFPSV (hepatitis B virus [HBV] nucleocapsid 18–27; reference 55) wherein we substituted the tyrosine with a cysteine to tag an FL group to the peptide: FLPSDC(FL)FPSV 54. The 27-mer polypeptides used for in vitro proteasome digestion were synthesized as described above, purified by reversed phase-HPLC in an acetonitrile–water gradient and lyophilized from acetonitrile–water overnight. Purity was confirmed by mass spectrometry.

The affinity of peptides for HLA-A*0201 was analyzed using the homozygous HLA-A*0201⁺ B-LCL JY as described previously 54, with minor adaptations. In brief, naturally bound peptides were stripped from the HLA-A*0201 molecules by exposing the JY cells for 90 s to ice-cold citric acid buffer with pH 3.1 (1:1 mixture of 0.263 M citric acid and 0.123 M Na₂HPO₄). Cells were immediately buffered with ice-cold IMDM containing 2% FCS, washed twice in the same medium, and resuspended in 2% FCS/IMDM containing 2 μg/ml human β₂-microglublin (Sigma-Aldrich). Subsequently, the stripped JY cells were plated at 4 × 10⁴/well in a 96-well V-bottomed plate together with 150 nM of a known high affinity HLA-A2*0201 binding FL-labeled reference peptide 55 and titrated concentrations of competitor test peptide. After incubation for 24 h at 4°C, cells were washed three times in PBS containing 1% BSA, fixed with 0.5% paraformaldehyde, and analyzed on a FACScan™ flow cytometer (Becton Dickinson). The percentage inhibition of FL-labeled reference peptide binding was calculated using the following formula: [1 − (MF_{reference and competitor peptide} − MF_{no reference peptide})/(MF_{reference peptide} − MF_{no reference peptide})] × 100%. The binding affinity of competitor peptide is expressed as the concentration needed to inhibit 50% binding of the FL-labeled reference peptide (IC₅₀). An IC₅₀ ≤ 5 μM was considered high affinity binding, 5 μM < IC₅₀ ≤ 15 μM was considered intermediate affinity binding, 15 μM < IC₅₀ ≤ 100 μM was judged low affinity binding, and IC₅₀ > 100 μM was considered not binding.

Binding stability at 37°C of peptides complexed with HLA-A*0201 was measured as described previously 56. In short, JY cells were treated with 10⁻⁴ M emetine (Sigma-Aldrich) for 1 h at 37°C to stop de novo synthesis of MHC class I molecules. Subsequently, endogenous bound peptides in HLA-A*0201 were removed by mild acid treatment (see above) and reconstituted with the peptide of interest at 200 μM in 2% FCS/IMDM containing 2 μg/ml human β₂-microglublin (Sigma-Aldrich) for 1.5 h at room temperature. Hereafter, cells were washed twice to remove free peptide and incubated at 37°C for 0, 2, 4, and 6 h. Subsequently, expressed HLA-A*0201–peptide complexes on JY cells were stained using the conformation-specific Moab BB7.2 and goat anti–mouse IgG–FITC and analyzed on a FACScan™ flow cytometer. The fluorescence index (FI) was calculated for each sample as: (MF_sample − MF_background)/MF_background, where MF_background is the value without peptide. The percentage of residual HLA-A*0201 molecules was calculated by equating for each peptide the FI of t = 2 h to 100% and then using the formula: % remaining = (FI_t=_n/FI_t=₂) × 100%. Because the dissociation of peptides from MHC is a linear process, the stability of the peptide–MHC complexes was measured as the time required for 50% of the molecules to decay (DT₅₀), starting from t = 2. By linear regression analysis of the sequential measurements plotted against the percentage of remaining HLA-A*0201 molecules, the DT₅₀ was calculated. As a positive control, the known highly stable HBV nucleocapsid 18–27 epitope was used.

20S proteasomes were purified from a B-LCL cell line as described 57. This cell type is known to contain immunoproteasomes 58. High LMP2 and LMP7 content was confirmed by two-dimensional immunoblotting (data not shown). To assess kinetics, digestions were performed with different incubation periods. Peptides (27 mer, 20 μg) were incubated with 1 μg of purified proteasome at 37°C for 1, 4, and 24 h in 300 μl proteasome digestion buffer as described 44. TFA (30 μl) was added to stop the digestion and samples were stored at −20°C before mass spectrometric analysis.

Electrospray ionization mass spectrometry was performed on a hybrid quadrupole time of flight mass spectrometer, a Q-TOF (Micromass), equipped with an on-line nanoelectrospray interface (capillary tip, 20-μm internal diameter × 90-μm outer diameter) with an approximate flow rate of 250 nl/min. This flow was obtained by splitting of the 0.4 ml/min flow of a conventional high pressure gradient system, using an Acurate flow splitter (LC Packings). Injections were done with a dedicated micro/nano HPLC autosampler, the FAMOS (LC Packings), equipped with two additional valves for phase system switching experiments. Digestion solutions were diluted five times in water/methanol/acetic acid (95:5:1, vol/vol/vol), and 1 μl was trapped on the precolumn (MCA-300-05-C8; LC Packings) in water/methanol/acetic acid (95:5:1, vol/vol/vol). Washing of the precolumn was done for 3 min to remove the buffers present in the digests. Subsequently, the trapped analytes were eluted with a steep gradient going from 70% B to 90% B in 10 min, with a flow of 250 nl/min (A, water/methanol/acetic acid [95:5:1, vol/vol/vol]; B, water/methanol/acetic acid [10:90:1, vol/vol/vol]). This low elution rate allows for a few additional mass spectrometry (MS)/MS experiments if necessary during the same elution. Mass spectra were recorded from mass 50–2,000 daltons every second with a resolution of 5,000 full width/half maximum (FWHM). The resolution allows direct determination of the monoisotopic mass, also from multiple charged ions. In MS/MS mode, ions were selected with a window of 2 daltons with the first quadrupole and fragments were collected with high efficiency with the orthogonal time of flight mass spectrometer. The collision gas applied was argon (4 × 10⁻⁵ mbar), and the collision voltage ∼30 V. The peaks in the mass spectrum were searched in the digested precursor peptide using the Biolynx/proteins software (Micromass) supplied with the mass spectrometer. The intensity of the peaks in the mass spectra was used to establish the relative amounts of peptides generated after proteasome digestion. The relative amounts of the peptides are given as a percentage of the total amount of peptide digested by the proteasome at the indicated incubation time.

Analysis of PRAME mRNA expression was determined by RT-PCR. Total cellular RNA was isolated with Trizol (GIBCO BRL) according to the manufacturer's procedure. RT reaction was performed on 5 μg of total RNA in a reaction volume of 25 μl with 5 μl of 5× reverse transcriptase buffer (Promega), 2.5 μl each of 10 mM deoxynucleotides (Amersham Pharmacia Biotech), 0.5 μg oligo dT₁₅ primer, 25 U of RNAsin (Promega), and 15 U avian myeloblastosis virus (AMV) reverse transcriptase (Promega). The RT reaction was incubated at 42°C for 60 min, heat inactivated for 10 min at 70°C, and diluted two times with water. For PCR amplification, 1 μl of reverse transcribed cDNA reaction mixture was used as a template. PCR primers used for the analysis of PRAME expression were OPC 189 (sense primer, 5′-CTGTACTCATTTCCAGAGCCAGA-3′) and OPC 190 (antisense primer, 5′-TATTGAGAGGGTTTCCAAGGGGTT-3′; reference 48). PCR conditions were 5 min at 94°C followed by 34 cycles consisting of 30 s at 94°C, 2 min at 64°C, and 3 min at 72°C.

PBMCs of two HLA-A*0201⁺ healthy donors (one donor for induction against PRA^300–309 and the other donor for inductions against PRA^100–108, PRA^142–151, PRA^425–433, and PRA^47–56) were obtained by the Ficoll-Paque method and used for CTL inductions. To optimally use all APCs present in PBMCs, we developed a culture system that yields a mix of activated B cells and mature DCs to be used as APCs during the primary induction step. PBMCs were separated in a T cell fraction and a fraction containing B cells and monocytes by SRBC rosetting. The T cell fraction was cryopreserved. The mixture of monocytes and B cells was cultured in 24-well plates at a concentration of 10⁶ cells/well in complete culture medium containing 800 U/ml GM-CSF (provided by S. Osanto, Leiden University Medical Center), 500 U/ml IL-4 (PeproTech), and 500 ng/ml CD40 mAb (clone B-B20; Serotec) for 6 d. This culture system achieved a threefold effect: (a) GM-CSF and IL-4 induced differentiation of monocytes into immature DCs 59, (b) IL-4 and CD40 mAbs caused activation and proliferation of B cells 60, and (c) CD40 mAb mediated maturation of immature DCs 61. At day 3, cytokines and CD40 mAb were replenished. To further promote CTL-inducing capacity, the APC mix was cultured for an additional 2 d with 0.4 ng/ml LPS (Difco Labs), 500 U/ml IFN-γ (Boehringer Mannheim), and 500 ng/ml CD40 mAb. At day 8 the APC mix was pulsed with 50 μg/ml peptide (each peptide separately) for 4 h at room temperature, irradiated (30 Gy), and washed to remove free peptide. The cryopreserved autologous T cell fraction was thawed and depleted from CD4⁺ T cells using magnetic beads (Dynal). The primary induction was performed in 96-well U-bottomed plates. APCs at a concentration of 10,000/well were cocultured with 50,000 CD8⁺ T cells/well in culture medium containing 10% human pooled serum (HPS), 5 ng/ml IL-7 (PeproTech), and 0.1 ng/ml IL-12 (Sigma-Aldrich). At day 7 after initiation of induction, the CTL microcultures were harvested (pooled), washed, and restimulated at a concentration of 40,000 responder cells/well of 96-well U-bottomed plates in culture medium containing 10% HPS, 5 ng/ml IL-7, and 0.1 ng/ml IL-12. Autologous-activated B cells, generated via the protocol described by Schultze et al. 60, irradiated (75 Gy), and peptide pulsed (50 μg/ml) for 4 h at room temperature in culture medium containing 2% FCS and 3 μg/ml β₂-microglublin (Sigma-Aldrich) after mild acid elution to remove naturally presented peptides from the MHC class I molecules (see Materials and Methods, MHC binding assay), were used at a concentration of 10,000 cells/well as restimulator APCs. Restimulations were repeated at day 14 and 21 in a similar way, with the exception of IL-7 being replaced by 20 IU/ml IL-2 (Chiron Corp.). At day 29, the CTL bulk culture was cloned by standard limiting dilution procedures. CTL clones were maintained by aspecific stimulation every 7 to 12 d using a feeder mixture consisting of allogeneic PBMCs and B-LCL in culture medium containing 10% FCS, 1.5% leucoagglutinin (Sigma-Aldrich), and 240 IU/ml IL-2.

CTL activity was measured in standard chromium release assays. In brief, after ⁵¹Cr labeling (1 h), target cells (2,000/well) were added to various numbers of effector cells in a final volume of 100 μl complete culture medium in 96-well U-bottomed plates. After 4 h incubation at 37°C, supernatants were harvested. The mean percentage of specific lysis of triplicate wells was calculated according to: (experimental release − spontaneous release)/(maximal release − spontaneous release) × 100%. For peptide titration experiments, ⁵¹Cr-labeled target cells (2,000/well) were pulsed with titrated amounts of peptide for 1 h at 37°C in 96-well plates. Subsequently, CTLs were added at an E/T ratio of 10. HLA class I blocking was accomplished by treatment of 2 × 10^{5 51}Cr-labeled M453 melanoma cells for 1 h with mAb W6.32 or control IgG2a at room temperature before addition to effector cells. Inhibition of proteasome function in melanoma FM3 was performed by treatment with 10 μM of lactacystin (Calbiochem) for 17 h during culture at 37°C. Thereafter, FM3 cells were harvested and ⁵¹Cr labeled for use in the cytotoxicity assay. Reconstitution of lysis by peptide was performed by pulsing lactacystin-treated and ⁵¹Cr-labeled FM3 cells for 30 min with 5 μM peptide.

To select candidate HLA-A*0201 binding peptides from PRAME, its aa sequence was screened for HLA-A*0201 binding motif containing peptides with a combination of two known binding prediction algorithms 62 63. Only peptides of 9 or 10 aa length were included, taking into account the low prevalence of HLA-A*0201–restricted CTL epitopes of 8 or 11 aa length 64. In total, 128 peptides (65 nonamers and 63 decamers) were synthesized in order to determine their actual binding affinity for HLA-A*0201 using a competition-based cellular binding assay 54. 19 high affinity binding peptides were identified (IC₅₀ ≤ 6 μM), and 27 peptides bound with intermediate affinity (6 μM < IC₅₀ ≤ 15 μM), whereas the other peptides displayed a low (15 μM < IC₅₀ ≤ 100 μM) or undetectable binding capacity (IC₅₀ > 100 μM; Table ). To more precisely define binding characteristics, peptide–MHC stability was assessed by measuring the dissociation rate of high affinity binding peptides complexed with HLA-A*0201 at 37°C 56. Two of the tested high affinity binding peptides (PRA^292–301 and PRA^190–199) showed a high off rate from HLA-A*0201, because <10% of HLA-A*0201–peptide complexes were detectable after 2 h incubation at 37°C. In previous work we have detected a strong correlation between MHC–peptide binding stability and immunogenicity in vivo 56. Therefore, PRA^292–301 and PRA^190–199 are, with respect to their binding characteristics, not likely to be efficiently presented in HLA-A*0201. For all other peptides, the 50% decay time (DT₅₀) was 2.5 h or longer (Table ), indicating a stable association with HLA-A*0201.

The two most important requirements for a peptide to be naturally presented as CTL epitope are: (a) proper excision from the protein by the proteolytic machinery and (b) sufficient binding affinity for HLA class I molecules. Therefore, we analyzed in vitro proteasome-mediated digestions of 27-mer polypeptides encompassing the 19 identified high affinity HLA-A*0201 binding peptides. Potential epitopes were primarily assessed for efficient liberation (i.e., by a major cleavage site at 1 h incubation) of their precise COOH terminus, which is a first requirement for the generation of most CTL epitopes 34 35 36 37. Intactness of the candidate epitope was evaluated as a secondary factor favoring efficient processing and presentation. 20S proteasomes isolated from a human EBV–transformed B cell line were used for digestions with 1-, 4-, and 24-h incubation periods, and mass spectrometry profiles of the digestion products were analyzed. Digestion patterns of four 27-mer polypeptides, all containing potential high affinity HLA-A*0201 binding epitopes, are shown in Fig. 1.

Fig. 1 A shows the digestions of PRAME 90–116, which harbors five HLA-A*0201 binding peptides (Table ) with their natural flanking residues. Of the COOH-terminal residues of the five HLA-A*0201 binding peptides, only Leu-108 was generated (fragments containing this COOH terminus added up to 8% at 1 h digestion). Therefore, both the 9-mer VLDGLDVLL (PRA^100–108) and the 10-mer AVLDGLDVLL (PRA^99–108) represent potential CTL epitopes. The NH₂ terminus of the epitope precursor is likely to be Lys-98, because the fragments most frequently generated were aa 90–97 and its complement aa 98–116, indicating an abundantly cleaved site after Phe-97.

Fig. 1 B shows the digestions of 27-mer PRAME 133–159, which contains 10-mer SLYSFPEPEA (PRA^142–151), the second best HLA-A*0201 binding peptide (Table ). Fragments sharing Ala-151 as COOH terminus added up to 29% at 1 h digestion, indicating an abundantly cleaved site after this residue. Furthermore, fragment aa 142–159 and the complementary fragment aa 133–141 were abundantly present, pointing to a major cleavage site after Ala-141. Thus, major cleavage sites were present just after and before SLYSFPEPEA, rendering this peptide a potential efficiently generated CTL epitope.

Fig. 1 C depicts digestions of PRAME 290–316 encompassing 10-mer ALYVDSLFFL (PRA^300–309), which bound best in HLA-A*0201 (Table ) and has its COOH terminus (Leu-309) in common with the already described HLA-A24–presented 9-mer LYVDSLFFL (PRA^301–309; reference 48). As might be expected on that basis, a cleavage site after Leu-309 was observed, because digestion fragments sharing this COOH terminus were abundantly generated after 1 h incubation. However, PRA^300–309 itself was found intact only after 24 h incubation at low quantities. This is probably due to cleavage sites within this potential epitope (after Val-303, Asp-304, and Leu-306). HLA-A*0201 binding peptides PRA^292–301 and PRA^294–303 (also in PRAME 290–316) were, respectively, not COOH-terminally generated and not found as intact fragment, indicating that these peptides are not likely to be naturally generated in the processing pathway.

Fig. 1 D shows the digestion pattern of PRAME 415–441, which harbors four peptides binding in HLA-A*0201 (Table ). The NH₂-terminally elongated decameric precursor ₄₂₄QSLLQHLIGL₄₃₃ of high affinity binding 9-mer SLLQHLIGL (PRA^425–433) was efficiently generated. The abundant generation of the COOH-terminal and NH₂-terminal counterparts of this 10-mer precursor (fragments aa 434–441 and aa 415–423, respectively) were also pointing to major cleavage sites just after and before ₄₂₄QSLLQHLIGL₄₃₃, indicating PRA^425–433, a potential CTL epitope. The three other HLA-A*0201 binding peptides were either not COOH-terminally excised (PRA^419–427 and PRA^422–430) or the correct COOH terminus was found only after 4 h incubation (PRA^422–431).

A concise representation of digestion analysis of 27-mers harboring all 19 high affinity binding peptides, including those discussed above, is shown in Fig. 2. Summarizing, 11 HLA-A*0201 binding peptides were either not COOH-terminally excised (PRA^47–56, PRA^435–443, PRA^292–301, PRA^182–191, PRA^248–256, PRA^100–108, and PRA^360–369) or the correct COOH terminus was generated only after 4 h incubation by a minor cleavage site (PRA^394–402, PRA^422–431, PRA^190–199, and PRA^419–427). The absence or late appearance of fragments containing the correct COOH terminus render these 11 peptides very unlikely to constitute naturally processed epitopes. Furthermore, three peptides were COOH-terminally liberated at 1 h digestion but only in very low quantities (<1%, data not shown; PRA^258–267, PRA^333–342, and PRA^462–470), whereas PRA^294–303 was not found as intact fragment. Consequently, it is doubtful that the latter peptides are efficiently generated in vivo. Only the high affinity binding peptides PRA^100–108, PRA^142–151, PRA^300–309, and PRA^425–433 were COOH-terminally excised by a major cleavage site at 1 h incubation and found intact in digestion fragments, indicating possible CTL epitopes (Fig. 1 and Fig. 2). Therefore, these four peptides were chosen for CTL inductions.

Separate CTL inductions, using PBMCs of healthy donors, were performed against VLDGLDVLL (PRA^100–108), SLYSFPEPEA (PRA^142–151), ALYVDSLFFL (PRA^300–309), and SLLQHLIGL (PRA^425–433) according to the protocol described in Materials and Methods. At day 28, the CTL bulk cultures were tested in a ⁵¹Cr release assay to asses peptide specificity. The CTL cultures raised against SLYSFPEPEA and SLLQHLIGL showed high specificity for targets loaded with the inducing peptide (at an E/T ratio of 5, both cultures reached 80% lysis compared with 20% lysis of targets loaded with a control peptide), whereas the other two CTL cultures displayed only slightly increased lysis of targets loaded with the relevant peptide (data not shown). The four CTL bulk cultures were cloned by limiting dilution at day 29. The peptide specificity of generated CTL clones was initially assessed in a split-well cytotoxicity assay. Despite low peptide specificity of CTL bulk cultures against VLDGLDVLL and ALYVDSLFFL, CTL clones specific for all four peptides were found. In summary, 51 of 576 (9%) CTL clones induced against VLDGLDVLL (PRA^100–108) showed specific lysis of peptide pulsed targets and 19 of 202 (9%) CTL clones raised against ALYVDSLFFL (PRA^300–309) displayed peptide specificity. As may be expected, higher percentages, namely 92% (279 of 304), of clones against SLYSFPEPEA (PRA^142–151) and 29% (97 of 336) of clones against SLLQHLIGL (PRA^425–433) showed peptide specificity. Based on peptide reactivity and growth characteristics, several CTL clones were functionally characterized in detail. For each specificity, one CTL clone is presented in this study. As shown in Fig. 3 A, representative CTL clones raised against the four different peptides all showed highly specific and efficient lysis of T2 cells pulsed with 5 μM of their inducing peptides at low E/T ratios. Peptide sensitivity of the CTL clones was determined in peptide titration experiments (Fig. 3 B). CTL no. 551 (anti-PRA^100–108) was able to half-maximally lyse targets loaded with VLDGLDVLL at ∼5 nM peptide. CTL no. 314, raised against SLYSFPEPEA (PRA^142–151), lysed T2 cells at half-maximal level when pulsed with <1 nM of the inducing peptide. CTL no. 460 (anti-PRA^300–309) was extremely sensitive in lysing T2 cells pulsed with ALYVDSLFFL: half-maximal lysis was reached at ∼3 pM peptide concentration. Finally, CTL no. 1257 (anti-PRA^425–433) was able to half-maximally lyse targets loaded with SLLQHLIGL at <12 nM. To analyze clonality of the CTL clones under investigation, we performed RT-PCR analysis with a panel of 24 primers of junctional regions of TCRB transcripts from 22 well-established TCRBV families to determine Vβ usage of the TCR 65. All CTL clones were shown to use a single Vβ, confirming clonality of the clones (data not shown).

Endogenous presentation of the candidate epitopes PRA^100–108, PRA^142–151, PRA^300–309, and PRA^425–433 in HLA-A*0201 was explored by assessing the ability of CTL clones that were raised against these peptides to specifically lyse melanoma cell lines M453 and FM3 expressing HLA-A*0201 (confirmed by flow cytometry, data not shown) and PRAME (determined by Northern blotting, data not shown). Both melanoma cell lines were efficiently lysed by all four CTL clones as measured in a ⁵¹Cr release assay, whereas the melanoma Mel603 expressing PRAME (assayed with RT-PCR, data not shown) but lacking HLA-A*0201 was not killed above background level (Fig. 4, top panel). Lysis of M453 was significantly inhibited after treatment of this target with HLA class I blocking mAb W6.32 (Fig. 4, middle panel), indicating that killing of M453 by these CTL clones involved HLA class I–restricted recognition. Furthermore, proteasome inhibition experiments with lactacystin were performed. Lysis of FM3 pretreated for 17 h with lactacystin (10 μM) was significantly diminished (Fig. 4, bottom panel). This indicated, in concordance with our in vitro proteasome digestion data, that generation of the four epitopes is proteasome dependent. To confirm PRAME as source of antigen naturally presented in HLA-A*0201, renal cell carcinoma cell line MZ1851, which is HLA-*0201⁺ but lacks PRAME expression, was transfected with full-length PRAME cDNA (MZ1851-PRAME). As shown in Fig. 5, PRAME expression (confirmed by RT-PCR) sensitized MZ1851-PRAME for lysis by a CTL clone directed against PRA^300–309.

To investigate HLA-A*0201–restricted presentation of PRA^100–108, PRA^142–151, PRA^300–309, and PRA^425–433 on tumor cells from histologic origins other than melanoma, we used panels of cell lines derived from various tumor types which have been reported to express PRAME 48 50.

Lysis by the selected CTL clones of tumor cell lines with or without HLA-A*0201 expression and naturally expressing PRAME or lacking PRAME expression was compared. HLA-A*0201 expression was confirmed by flow cytometry (data not shown) and PRAME expression by RT-PCR or Northern blotting (data not shown). Lysis of the HLA-A*0201⁺ renal cell carcinoma (RCC) cell line MZ1851, which lacks PRAME expression, was compared with lysis of RCC cell lines MZ1257 and MZ1774, both expressing HLA-A*0201 and PRAME. The CTL clones reactive against the four different PRAME peptides showed significant lysis of the two PRAME⁺ cell lines but not of MZ1851, again confirming PRAME as the source of target antigens (Fig. 6, top panel). Likewise, lysis of lung carcinoma cell lines was HLA-A*0201 restricted and PRAME specific, because only GLC36 expressing HLA-A*0201⁺ and PRAME⁺, and not GLC02, which is PRAME⁺ but lacks HLA-A*0201 expression, was killed (Fig. 6, middle panel). Mammary carcinoma cell line MCF7 (HLA-A*0201⁺ and PRAME⁺) was killed efficiently as well, whereas cell line ZR-75-1, which lacks HLA-A*0201 but expresses PRAME, was not lysed above background level (Fig. 6, bottom panel). Finally, HPV16⁺ cervix carcinoma cell line C33 and osteosarcoma cell line SAOS, both HLA-A*0201⁺ and PRAME⁺, were efficiently killed by the CTL clones (data not shown), underscoring the broad expression pattern of the PRAME epitopes by tumors. Taken together, we observed a consistent lysis of tumor cell lines when both the relevant MHC molecule and the tumor Ag were expressed. These results indicate that PRA^100–108, PRA^142–151, PRA^300–309, and PRA^425–433 are presented by HLA-A*0201 on a broad array of tumor cell lines.

To further validate our epitope prediction procedure and investigate possible false negative epitope prediction, CTLs were induced against the highest affinity HLA-A*0201 binding peptide that was not generated in vitro by proteasome-mediated breakdown: LLPRELFPPL (PRA^47–56; Table and Fig. 2). Digestion of the 27-mer PRAME 37–63 showed that the COOH terminus of LLPRELFPPL was not generated. Instead, cleavage sites were observed after Leu-45, Met-58, and Ala-59 (Fig. 2). Dual cleavage fragments ₄₆ELLPRELFPPLFM₅₈ and ₄₆ELLPRELFPPLFMA₅₉ were abundantly found at 1 h digestion (data not shown). Using the same induction protocol as used for the four identified epitopes, CTLs were generated against LLPRELFPPL. Three CTL clones recognizing this peptide with high affinity were tested for lysis of PRAME and HLA-A*0201–expressing tumor cell lines at different E/T ratios (Table ). For comparison, three CTL clones recognizing the SLYSFPEPEA epitope (PRA^142–151) with equal affinity as the affinity of CTL anti-PRA^47–56 for LLPRELFPPL were included in the same experiment. The results show that CTLs raised against LLPRELFPPL do not lyse any of the tumor cell lines, whereas the same targets were efficiently killed by the control CTLs directed against SLYSFPEPEA (Table ). These data strongly suggest that LLPRELFPPL is not endogenously generated, supporting the accuracy of our epitope prediction procedure and the relevance of the proteasome digestion analysis. In addition to these data, high affinity CTL clones generated against three different BCR-ABL fusion protein–derived peptides failed to recognize BCR-ABL–expressing target cells (data not shown). Subsequent analysis of in vitro processing of these peptides showed that the proteasome did not generate the COOH terminus of any of these high affinity HLA class I binding peptides. These results confirm the importance of proper proteasomal cleavage for the generation of HLA class I–presented epitopes.